Clinical trials: insulin glargine
Gestational Diabetes Mellitus, Pregnancy in Diabetic
Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER)
We propose a pragmatic, unblinded, randomized controlled, single center trial of 56 pregnant individuals with Gestational diabetes mellitus (GDM).
- Conditions
- Gestational Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy, High Risk
- Trial name
- NCT05922033
- Testing
- Patient-led Insulin (intervention group), Provider-led Insulin (standard care)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Ohio State University
Type 2 Diabetes Treated With Insulin
Premixed vs Basal Bolus Insulin Therapy in Older Patients With Type 2 Diabetes
The purpose of this study is to compare efficacy and security of premixed insulin treatment vs basal bolus insulin treatment in older patients with poorly controlled type 2 diabetes.
- Trial name
- NCT04739241
- Testing
- premixed insulin therapy, basal bolus insulin therapy
- Volunteers
- 60 people
- Sponsor
- Consorci Sanitari Integral
Diabetes Mellitus
Glucose Control With Multiple Daily Insulin Injections In Diabetic Patients Hospitalized In A General Medicine Ward
At least 20% of patients hospitalized in the general medical and surgical wards at any given time suffer from diabetes. It has been demonstrated that poor clinical outcome correlates with the degree of hyperglycemia in these…
- Trial name
- NCT00464854
- Testing
- Glargine and insulin aspart or lispro
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Assaf-Harofeh Medical Center
Diabetes Mellitus
Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient
The purpose of this research study is to test the safety and efficacy of a drug called saxagliptin (Onglyza) for treatment of type 2 diabetes in non-critically ill hospitalized patients who have an HbA1c of 7.5 or lower, on 1 or…
- Trial name
- NCT02182895
- Testing
- Saxagliptin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Brigham and Women's Hospital
Diabetes Mellitus
The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning Dosing
To compare the percentage of subjects with a glucose measurement < than or = to 56 mg/dL at any point of the 8-point glucose profiles during 3 consecutive days before vs.
- Trial name
- NCT00609895
- Testing
- INSULIN GLARGINE
- Where
- Mexico
- Volunteers
- 22 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Effect of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) is characterized by wide fluctuations of glucose. The long-acting insulin has showed to improve glycemic variability however the behavior of insulin glargine versus insulin degludec is unknown.
- Trial name
- Diabetes (NCT02680457)
- Testing
- Insulin Degludec, Insulin Glargine
- Where
- Mexico
- Volunteers
- 12 people
- Sponsor
- University of Guadalajara
Type 2 Diabetes
Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes
High blood glucose levels in hospitalized patients with diabetes are associated with increased risk of medical complications and death.
- Trial name
- NCT01845831
- Testing
- Sitagliptin, Basal Bolus, Metformin and Sitagliptin
- Where
- 5 sites in United States
- Volunteers
- 292 people
- Sponsor
- Emory University
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)
This is an active- and placebo-controlled, single-site, four-part trial of MK-1092 in healthy adult participants, in participants with type 1 diabetes mellitus (T1DM), and in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03170544
- Testing
- MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 1
A Study for Patients With Type 1 Diabetes
Comparison of blood glucose levels in patients with Type 1 diabetes when they take a new basal insulin analog and when they take insulin glargine
- Trial name
- NCT01049412
- Testing
- LY2605541, Insulin glargine
- Where
- 13 sites in United States, Israel
- Volunteers
- 138 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy
The purpose of this studay is to compare the efficacy of different hypoglycemic regimens versus twice-daily premixed insulin in type 2 diabetes mellitus (T2DM) patients after short-term ntensive Insulin Therapy by using…
- Trial name
- NCT05545800
- Testing
- metformin+empagliflozin+insulin glargine, IDegLira, premixed insulin analogues
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Xiangya Hospital of Central South University
Hyperglycemia
Prospective Study of Personalized Approach to Inpatient Patients With Hyperglycemia
The purpose of this study is to compare the outcomes between hospitalized cancer patients with high blood sugar receiving the current standard of care of administering insulin, and hospitalized cancer patients receiving a new…
- Trial name
- NCT03904199
- Testing
- Insulin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Type 1 Diabetes
Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes
We hypothesize that checking blood sugar and taking long and short acting insulin before lunch at school may improve overall blood sugar control, grades, and decreases school absences in children and teens with poorly controlled…
- Trial name
- NCT00340613
- Testing
- glargine insulin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Baylor College of Medicine
Type 2 Diabetes Mellitus
A Study for Type 2 Diabetic Patients
The purpose of the study is to compare the insulin lispro low mixture (1, 2 or 3 daily injections) with insulin glargine (alone or with 1, 2 or 3 insulin lispro daily injections) on lowering the blood sugar level
- Trial name
- NCT00548808
- Testing
- Insulin lispro low mixture, Insulin glargine, Insulin lispro
- Where
- 25 sites in Australia, Brazil and 5 more
- Volunteers
- 426 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes
A study to evaluate the efficacy and safety of Human Insulin Inhalation Powder [also known as AIR® Inhaled Insulin][AIR® is a registered trademark of Alkermes,Inc.] in patients with Type 2 diabetes who are currently being treated…
- Trial name
- NCT00355849
- Testing
- Human Insulin Inhalation Powder, Insulin Glargine
- Where
- 69 sites in United States, Brazil and 10 more
- Volunteers
- 555 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy
Primary Outcomes: Average decrease in A1c from baseline to end of Study Phase (52 weeks) for subjects in the "722 Group" is greater than that for subjects in the "Control (MDI) Group".
- Trial name
- STAR3 (NCT00417989)
- Testing
- MiniMed Paradigm REAL-Time System
- Where
- 30 sites in United States, Canada
- Volunteers
- 485 people
- Sponsor
- Medtronic MiniMed, Inc.
Atherosclerosis, Cardiovascular Diseases
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and…
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension
- Trial name
- ACCORD (NCT00000620)
- Testing
- Anti-hyperglycemic Agents, Anti-hypertensive Agents
- Where
- 7 sites in United States, Canada
- Volunteers
- 10,251 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Diabetes Mellitus Type 1
Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis
Hypothesis: Basal insulin analogs with continuous 24-hour delivery of insulin improve glycemic control during the first year of treatment of children/adolescents with type 1 diabetes mellitus (T1DM)by preserving endogenous…
- Trial name
- BAS (NCT01271517)
- Testing
- NPH insulin, Glargine, Detemir
- Where
- Sweden
- Volunteers
- 120 people
- Sponsor
- Karolinska Institutet
Type 1 Diabetes
Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH
To determine whether using a long-acting insulin analog at the time of diagnosis, instead of intermediate-acting insulin, affects the rate of loss of the body's ability to make insulin in children with newly diagnosed type 1…
- Trial name
- NCT00564018
- Testing
- Insulin detemir, Glargine, NPH
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Texas Southwestern Medical Center
Type 2 Diabetes Mellitus
Therapies on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity Which Protect Islet β Cell
Prevalence of diabetes is increasing rapidly both in China and all over the world.Hyperglycemia is an important risk factor and major hazard to cardiovascular and cerebrovascular diseases and even dangerous to human health."High…
- Trial name
- TOND (NCT03180281)
- Testing
- DPP4, Insulin, SU
- Where
- China
- Volunteers
- 135 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Diabetes Mellitus, Type 2
RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan
The purpose of the study is to collect information on how Ryzodeg® works in real world participants. Participants will get Ryzodeg® as prescribed to them by the study doctor. The study will last for about 6 to 8 months.
- Trial name
- RESILIENT (NCT03745157)
- Testing
- Insulin Degludec/Insulin Aspart
- Where
- 29 sites in Japan
- Volunteers
- 246 people
- Sponsor
- Novo Nordisk A/S